Cytostatic inhibition of cancer cell growth by lignan secoisolariciresinol diglucoside.
Our previous study demonstrated that lignan metabolites enterolactone and enterodiol inhibited colonic cancer cell growth by inducing cell cycle arrest and apoptosis. However, the dietary lignans are naturally present as glycoside precursors, such as secoisolariciresinol diglucoside (SDG), which have not been evaluated yet. This study tested the hypothesis that dietary SDG might have a different effect than its metabolites in human colonic SW480 cancer cells. Treatment with SDG at 0 to 40 μmol/L for up to 48 hours resulted in a dose- and time-dependent decrease in cell numbers, which was comparable to enterolactone. The inhibition of cell growth by SDG did not appear to be mediated by cytotoxicity, but by a cytostatic mechanism associated with an increase of cyclin A expression. Furthermore, high-performance liquid chromatography analysis indicated that SDG in the media was much more stable than enterolactone (95% of SDG survival vs 57% of enterolactone after 48-hour treatment). When the cells were treated with either enterolactone or SDG at 40 μmol/L for 48 hours, the intracellular levels of enterolactone, as measured by high-performance liquid chromatography-mass spectrometry/electron spray ionization, were about 8.3 × 10(-8) nmol per cell; but intracellular SDG or potential metabolites were undetectable. Taken together, SDG demonstrated similar effects on cell growth, cytotoxicity, and cell cycle arrest when compared with its metabolite enterolactone. However, the reliable stability and undetectable intracellular SDG in treated cells may suggest that metabolism of SDG, if exposed directly to the colonic cells, could be different from the known degradation by microorganisms in human gut.
Department of Human Nutrition, Kansas State University, Manhattan, KS 66506, USA.
Allan
A
Ayella
Soyoung
S
Lim
Yu
Y
Jiang
Takeo
T
Iwamoto
Dingbo
D
Lin
John
J
Tomich
Weiqun
W
Wang
D015107:4-Butyrolactone / Q000031:analogs & derivatives / Q000494:pharmacology; D000230:Adenocarcinoma / Q000178:diet therapy / Q000517:prevention & control*; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002072:Butylene Glycols / Q000494:pharmacology*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D002851:Chromatography, High Pressure Liquid; D003110:Colonic Neoplasms / Q000178:diet therapy / Q000517:prevention & control*; D019925:Cyclin A / Q000378:metabolism; D054697:Cytostatic Agents / Q000494:pharmacology*; D004040:Dietary Carbohydrates / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005960:Glucosides / Q000494:pharmacology*; D006027:Glycosides / Q000378:metabolism; D006801:Humans; D017705:Lignans / Q000494:pharmacology; D013058:Mass Spectrometry
D016588:Anticarcinogenic Agents; D002072:Butylene Glycols; D019925:Cyclin A; D054697:Cytostatic Agents; D004040:Dietary Carbohydrates; D005960:Glucosides; D006027:Glycosides; D017705:Lignans; D015107:4-Butyrolactone; C090142:secoisolariciresinol diglucoside; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone